2023
Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?
Merkin R, Chiang V, Goldberg S. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Therapeutic Advances In Medical Oncology 2023, 15: 17588359231175438. PMID: 37275964, PMCID: PMC10233588, DOI: 10.1177/17588359231175438.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsBrain metastasesTargetable genetic alterationsLocal therapyLung cancerStereotactic radiosurgeryDeath 1 ligand 1 expressionManagement of BMSole metastatic siteStage IV diseaseWhole brain radiotherapyLigand 1 expressionPD-L1 expressionProspective clinical trialsTime of diagnosisManagement of patientsCell lung cancerCancer-related deathGenetic alterationsCentral nervous systemGenetic driver alterationsAnaplastic lymphoma kinaseEpidermal growth factor receptorGrowth factor receptorUpfront radiotherapy
2015
Evolution of multidisciplinary brain metastasis management: case study and literature review.
Colaco R, Martin P, Chiang V. Evolution of multidisciplinary brain metastasis management: case study and literature review. The Yale Journal Of Biology And Medicine 2015, 88: 157-65. PMID: 26029014, PMCID: PMC4445437.Peer-Reviewed Original ResearchConceptsBrain metastasesManagement of BMProgression-free survivalLocal tumor controlLong-term survivorsNeurocognitive side effectsBrain metastasis managementSymptom reliefTumor burdenTumor controlCancer patientsTreatment modalitiesMetastasis managementSide effectsRadiation modalitiesFunctional independenceContemporary managementPatientsLiterature reviewSurvivalModalitiesOverall qualityCoordinated approachManagementPrognosis